Metabolic syndrome in patients with hematological diseases

C. Annaloro(University of Milan), Lorena Airaghi(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Francesco Onida(Peter MacCallum Cancer Centre), Giorgia Saporiti(University of Milan), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico)

Expert Review of Hematology

August 1, 2012

10.1586/ehm.12.35

Cited by 16

Related Papers

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

|Blood|2009|433

Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model

|Journal of Clinical Oncology|2015|419

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial

|Journal of Clinical Oncology|2016|394

Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients

|Blood|2014|373

Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

|Blood|2023|330